Clinical evidence demonstrates that GLP-1 receptor agonists (GLP-1RAs) confer dual benefits in DM-COPD comorbidity: reducing asthma exacerbation risk (Foer et al., 2023), while ameliorating bronchial hyperresponsiveness via PKA activation in airway epithelial cells (Rogliani et al., 2016). Here, GLP1R is linked to diabetes mellitus.